Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRN01941 in Healthy Volunteers
NCT03936166Phase 1Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CRN01941 in neuroendocrine tumors (NETs) (3 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Number of participants with treatment emergent adverse events by severity, Number of participants with serious adverse events (SAEs) and 3 more. Started Apr 2019; status: completed.
02
Drugs
CRN01941
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03936166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936166.